Cytosolic PLA2 is required for CTL-mediated immunopathology of celiac disease via NKG2D and IL-15 by Tang, Fangming et al.
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
ARTICLE
The Rockefeller University Press  $30.00
J. Exp. Med. Vol. 206 No. 3  707-719
www.jem.org/cgi/doi/10.1084/jem.20071887
707
        NKG2D is a NK cell receptor expressed by all 
human CTLs (  1  ) that recognizes MHC class I–
related chain (MIC) and UL-16  –  binding pro-
tein (ULPB) molecules expressed on stressed 
and transformed target cells (  1  –  3  ). NKG2D has 
been implicated in antitumor immunity medi-
ated by both NK cells and CTLs (  4, 5  ) and in 
T cell–mediated immune disorders such as ce-
liac disease (  6, 7  ), rheumatoid arthritis (  8  ), and 
NOD mouse model for juvenile type 1 diabe-
tes (  9  ). In humans, NKG2D associates exclu-
sively with DAP10 (  6, 10  –  12  ), an adaptor with 
a YINM cytoplasmic tail motif that activates 
phosphatidylinositol 3-kinase (PI3-K) (  10  ), but 
not the syk/ZAP-70 kinase family. Because of 
these similarities with the CD28 signaling path-
way, NKG2D–DAP10 was initially thought to 
function mainly as a co-stimulator (  1  ) and to 
play a role in autoimmunity by promoting acti-
vation of autoreactive T cells. However, sev-
eral studies indicate that NKG2D–DAP10 in 
human can also mediate cytolysis independently 
of TCR engagement in eff  ector CTLs exposed 
to IL-15 or high doses of IL-2 (  6, 13, 14  ). This 
layer of eff  ector T cell regulation by NKG2D 
at the level of cytolysis may serve to eff  ectively 
and rapidly eliminate infected or transformed 
target tissue cells independently of antigen spec-
ifi  city, and may participate in aberrant tissue de-
struction in diseases in which IL-15 expression is 
dysregulated (for review see reference [  15  ]). 
  The downstream co-stimulatory and cyto-
lytic signaling pathways recruited by NKG2D 
in CTLs remain incompletely characterized. 
Intriguingly, several studies suggest that cPLA  2   
may be involved in infl   ammatory and auto-
immune diseases ( 16  –  18  ). However, how cPLA  2   
drives immunopathological processes and whe-
ther it involves CTLs is poorly understood. 
CORRESPONDENCE  
 Bana  Jabri: 
 bjabri@bsd.uchicago.edu
  Abbreviations used: AA, arachi-
donic acid; BLT, benzyloxycar-
bonyl lysine thiobenzyl; COX, 
cyclooxygenase; cPLA  2  , cyto-
solic phospholipase A2; ERK, 
extracellular signal  –  regulated 
kinase; IE-CTL, intraepithelial 
CTL; ITAM, immunoreceptor 
tyrosine-based activation motifs; 
JNK, c-Jun N-terminal kinase; 
LA, linoleic acid; MIC, MHC 
class I–related chain; PI3-K, 
phosphatidylinositol 3-kinase; 
PB-CTL, peripheral blood 
CTL; siRNA, small interfering 
RNA; ULPB, UL-16  –  binding 
protein. 
    F. Tang and Z. Chen contributed equally to this paper.   
  Cytosolic PLA  2   is required for CTL-
mediated immunopathology of celiac 
disease via NKG2D and IL-15 
    Fangming     Tang  ,    1       Zhangguo     Chen  ,    1       Cezary     Ciszewski  ,    1       Mala     Setty  ,    2     
  Jason     Solus  ,    1       Maria     Tretiakova  ,    1       Ellen     Ebert  ,    5       Jin     Han  ,    1       Anning     Lin  ,    3     
  Stefano     Guandalini  ,    2      Veronika     Groh  ,    6       Thomas     Spies  ,    6       Peter     Green  ,    7     
and   Bana     Jabri      1,2,4     
  1  Department of Pathology,   2  Department of Pediatrics,   3  Ben May Institute for Cancer Research, and   4 Department 
of Medicine, University of Chicago, Chicago, IL 60637 
  5  Department of Medicine, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ 08903 
  6  Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 
  7  Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY 10032     
  IL-15 and NKG2D promote autoimmunity and celiac disease by arming cytotoxic T lympho-
cytes (CTLs) to cause tissue destruction. However, the downstream signaling events under-
lying these functional properties remain unclear. Here, we identify cytosolic phospholipase 
A  2   (cPLA  2  ) as a central molecule in NKG2D-mediated cytolysis in CTLs. Furthermore, we 
report that NKG2D induces, upon recognition of MIC  +   target cells, the release of arachi-
donic acid (AA) by CTLs to promote tissue infl  ammation in association with target killing. 
Interestingly, IL-15, which licenses NKG2D-mediated lymphokine killer activity in CTLs, 
cooperates with NKG2D to induce cPLA  2   activation and AA release. Finally, cPLA  2   activa-
tion in intraepithelial CTLs of celiac patients provides an in vivo pathophysiological dimen-
sion to cPLA  2   activation in CTLs. These results reveal an unrecognized link between NKG2D 
and tissue infl  ammation, which may underlie the emerging role of NKG2D in various immuno-
pathological conditions and defi  ne new therapeutic targets. 
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not control siRNA. In contrast, TCR-mediated cytolysis re-
mained essentially intact for this level of specifi  c cytolysis (  Fig. 
1 B  , middle). The level of inhibition observed for NKG2D-
mediated cytolysis was highly signifi  cant considering that some 
residual cPLA  2   could be detected (  Fig. 1 B  , left). Second, simi-
lar results were obtained when using MIC  +  C1R target cells 
(  Fig. 1 D  ). Importantly, addition of AA (  Fig. 1 D  ), but not a 
control polyunsaturated fatty acid, linoleic acid (LA), rescued 
NKG2D-mediated cytolysis (  Fig. 1 D  , right). The assays were 
performed either with global unsorted siRNA-transfected 
CTLs (  Fig. 1, B and D  , right), or with CTLs sorted into GFP  +  -
transfected and GFP       -untransfected CTLs (  Fig. 1 D  , middle). 
  Having shown that cPLA  2   played a role in NKG2D-medi-
ated cytolysis, we wanted to more specifi  cally demonstrate its 
role in the release of cytolytic granules. We previously re-
ported, that ligation of NKG2D receptors expressed on CTLs 
with monoclonal anti-NKG2D mAb triggered granule release 
using a BLT esterase assay (  6  ). As anticipated, knock down of 
cPLA  2   by siRNA (  Fig. 1 C  ) blocked degranulation. Similar re-
sults were obtained in the presence of the pharmacological in-
hibitor CF3 (unpublished data). Importantly, cPLA  2   inhibition 
did not aff  ect the level of granzyme and perforin expression in 
CTLs (Fig. S2, available at http://www.jem.org/cgi/content/
full/jem.20071887/DC1), further suggesting that cPLA  2   plays 
a role in NKG2D-mediated degranulation. 
  Interestingly, cPLA  2   inhibition by AACOCF3 or knock 
down by siRNA aff  ected only marginally TCR-mediated 
cytolysis (  Figs. 1 and 2  ). 
  Altogether, these results demonstrate that cPLA  2   and AA 
play a critical role in NKG2D-mediated, but not TCR-me-
diated, cytolytic granule exocytosis in eff  ector CTLs. 
  cPLA  2   plays a critical role in NKG2D-mediated cytolytic 
co-stimulatory functions 
  NKG2D was shown to function as a co-stimulatory receptor 
that enhances TCR-dependent cytolytic responses (  13, 29  ). 
We therefore investigated whether cPLA  2   was also implicated 
in NKG2D cytolytic co-stimulatory functions. This study 
had to be performed in CTLs grown in medium with low 
IL-2, in which NKG2D was not licensed to mediate direct 
killing. As previously reported (  29  ), NKG2D signifi  cantly in-
creased TCR-mediated cytolysis in two distinct PB-CTL 
clones (  Fig. 2  ).   Importantly, cPLA  2   inhibition prevented 
NKG2D enhancement of TCR-mediated cytolysis, and AA 
signifi   cantly rescued NKG2D co-stimulation (  Fig. 2  ). In 
contrast, cPLA  2   inhibition had little or no signifi  cant eff  ect 
on TCR-mediated cytolysis (  Fig. 2  ). 
  In summary, these observations also support a role for 
cPLA  2   in NKG2D cytolytic co-stimulatory functions. 
  NKG2D induces cPLA  2   activation and AA release 
in effector CTLs 
  To establish a biochemical basis for cPLA  2   functions in CTLs, 
we determined NKG2D-induced cPLA  2   phosphorylation and 
AA release in several diff  erent CTL subsets, including in IE-
CTL clones derived from celiac patients. Expression of cPLA  2   in 
Interestingly, several reports point to a potential role of 
cPLA  2   in T cell proliferation (  19, 20  ). Furthermore, cPLA  2   
was shown to be involved in granule exocytosis by neuronal 
cells (  21, 22  ), hormonal cells (  23  ), and granulocytes (  24  –  27  ), 
suggesting that it might also be implicated in granular release 
occurring in the context of cytolysis and cytokine secretion 
in T cells. Finally, cPLA  2   activation by surface receptors is 
dependent on phosphorylation at Ser  505   by MAP kinases (  28  ), 
and NKG2D induces c-Jun N-terminal kinase (JNK) and ex-
tracellular signal  –  regulated kinase (ERK) activation in CTLs 
(  6  ). Together, these observations prompted us to examine a 
potential link between cPLA  2   and NKG2D eff  ector function 
in CTLs and its relevance in celiac disease. 
    RESULTS   
  cPLA  2   plays a critical role in direct NKG2D-
mediated cytolysis 
  NKG2D is licensed to mediate cytolysis independently of 
TCR activation in CTLs when they are in an eff  ector stage 
and in the presence of IL-15 or high doses of IL-2 (  6  ). Im-
portantly, under these conditions it is possible to assess how 
cPLA  2   aff  ects NKG2D eff  ector functions independently from 
other receptors. To determine that our fi  ndings were not re-
stricted to a particular subset of eff  ector CTLs, we analyzed 
the eff  ect of cPLA  2   inhibition in a variety of eff  ector CTLs. 
Specifi   cally, we studied freshly isolated eff  ector  intestinal 
intraepithelial CTLs (IE-CTLs) that were prestimulated in 
vitro with IL-15, normal IE-CTL clones, IE-CTL clones 
derived from celiac patients, peripheral blood eff  ector CTL 
(PB-CTL) clones, and the leukemia TALL-104 CD8 T cell 
line. This latter cell line was previously used as a model to 
study the NKG2D cytolytic signaling pathway (  6  ). All clones 
and cell lines were grown in the presence of a high concen-
tration of IL-2, which is known to substitute for IL-15. 
  The cPLA  2   inhibitor AACOCF3 (CF3) impaired NKG2D-
mediated cytolysis in antibody-redirected cytolytic assays 
(  Fig. 1 A  , left).   Importantly, this fi  nding could be extended 
to cytolytic assays using MIC-transfected C1R cells as tar-
gets (  Fig. 1 A  , right). Furthermore, arachidonic acid (AA) 
signifi  cantly restored cytolysis, strongly arguing against a non-
specifi  c eff  ect of the cPLA  2   inhibitor AACOCF3 (  Fig. 1 A  , 
right). Finally, AACOCF3 and AA had a dose-dependent 
eff  ect on NKG2D-mediated cytolysis in freshly isolated IE-
CTLs (Fig. S1, available at http://www.jem.org/cgi/content/
full/jem.20071887/DC1). 
  To further assess the critical role of cPLA  2   in NKG2D-
  mediated cytolysis and granule release, cPLA  2   was   “  knocked 
down  ”   in TALL-104 (  Fig. 1, B and C  ) and PB-CTLs (  Fig. 1 B  , 
right) using cPLA  2   small interfering (si)RNA. Importantly, 
cPLA  2   siRNA specifi  cally targeted cPLA  2   expression, as it af-
fected neither ERK nor JNK expression (not depicted) and ac-
tivation (  Fig. 1 B  , left), nor 5-lipoxygenase (5-LO) expression 
(  Fig. 1 C  , left). The eff  ect of cPLA  2   knock down on NKG2D-
mediated cytolysis was assessed in two ways. First, in redirected 
cytolytic assays, as expected, NKG2D-mediated cytolysis was 
inhibited by up to 50% in the presence of cPLA  2   siRNA, but JEM VOL. 206, March 16, 2009 
ARTICLE
709
  To further assess the ability of NKG2D to activate cPLA  2  , we 
studied perinuclear translocation of cPLA  2   and cPLA  2   activity 
in IE- and PB-CTLs. As anticipated, NKG2D engagement in-
duced perinuclear translocation of cPLA  2   (Fig. S3 A, available 
at http://www.jem.org/cgi/content/full/jem.20071887/DC1) 
mature T cells has been controversial (  19, 30  ). However, using 
Western blot analysis, we demonstrated cPLA  2   expression in 
diff  erent eff  ector CTLs (  Fig. 3,   left).   Furthermore, as shown in 
  Fig. 3  , NKG2D cross-linking induced cPLA  2   phosphorylation 
in a dose-dependent manner (  Fig. 3,   left). 
    Figure 1.     NKG2D-mediated cytolysis in CTL is cPLA  2   dependent.  (A)  cPLA 2   inhibition by the pharmacological inhibitor AACOCF3 (CF3) blocks 
NKG2D-mediated cytotoxicity. Fresh IE-CTL prestimulated with IL-15 for 48 h, celiac IE-CTL clones, PB-CTL clones, and TALL-104 leukemia CTLs were pre-
treated for 30 min with vehicle control or CF3 before the cytolysis assay. Depending on the nature of the CTLs studied, distinct E/T ratios were used to 
achieve similar levels of specifi  c lysis (50:1 for fresh IE-CTLs and PB-CTLs, 15:1 for celiac IE-CTLs, and 5:1 for TALL-104 leukemia CTLs). Data are means   ±   
SD of three independent experiments for each cell line. P values reported are from a Tukey-adjusted pairwise comparison. (left) Cytolysis of Fc   R +   P815 
cells was signifi  cantly blocked by 20   μ  M CF3 in the presence of anti-NKG2D, but not anti-CD3, antibody. (right) Cytolysis of C1R/MIC transfectants was 
blocked upon pretreatment of CTLs with 20   μ  M CF3 and restored when 100   μ  M AA was added 1 h after the beginning of the cytolysis assay. Importantly, 
CF3 did not affect the level of intracellular granzyme and perforin expression (Fig. S2). (B) Knockdown of cPLA  2   in TALL-104 CTLs signifi  cantly impairs 
NKG2D-mediated cytolysis, but not TCR-mediated cytolysis under optimal conditions of stimulation. Untransfected cPLA  2   and control siRNA-transfected 
TALL-104 CTLs were studied 72 h after transfection. (left) cPLA  2   siRNA  signifi  cantly decreases cPLA  2   expression without affecting JNK and ERK activation. 
Untransfected and transfected TALL-104 were cultured for 72 h, serum-starved overnight, and stimulated for 5 min (p-ERK) or 15 min (p-JNK), respec-
tively, with anti-NKG2D. Cell lysates were analyzed by Western blot with anti-cPLA  2  , then stripped and blotted with anti-phospho-ERK (p-ERK) or -JNK (p-
JNK) mAbs.   Right panel:   cPLA 2   siRNA inhibited signifi  cantly NKG2D-mediated cytolysis in a redirected cytolytic assay using   51 Cr-labeled  Fc  R +   P815 
targets. (C) cPLA  2   knocked down in PB-CTLs blocked the release of cytolytic granule. An esterase assay was performed 36 h after transfection. Data are 
means   ±   SD of six experimental points from two independent experiments. P values are from a Tukey-adjusted pairwise comparison. (D) AA reconstitutes 
NKG2D cytolytic function against C1R/MIC  +   target cells in TALL-104 transfected with cPLA  2   siRNA. Rescue experiments were performed by adding 50   μ  M 
of AA or a control polyunsaturated fatty acid LA after 1 h co-culture with target cells. (left) Knock-down of cPLA  2   did not affect 5-LO expression, whereas 
5-LO siRNA decreased signifi  cantly 5-LO expression without affecting cPLA  2   expression. Cells were sorted into transfected (GFP  +  ) and untransfected cells 
(GFP  -  ) cell populations 24 h after transfection with cPLA  2   siRNA, control siRNA or 5-LO siRNA in addition to GFP plasmids. Cell lysates were analyzed 12 h 
later by Western blot with anti-cPLA  2   antibody, then stripped and immunoblotted with anti-5-LO antibody. (middle) Cytolysis assays were performed 36 h 
after transfection at the indicated E:T ratios in transfected (GFP  +  ) and untransfected (GFP  -  ) cells. One representative experiment out of two independent 
experiments is shown. (right) Cells were cultured for 72 h after transfection with cPLA  2   or control siRNA and cytolysis assays were performed in absence 
of cell sorting on the total cell population. The transfection effi  ciency, determined by GFP expression, was     60%. Data are means   ±   SD of six experimen-
tal points from two independent experiments. P values are from a Tukey-adjusted pairwise comparison.     710 CPLA  2  , IL-15, AND NKGD CYTOLYTIC FUNCTIONS   | Tang et al. 
  To determine whether the capacity of NKG2D to induce 
cPLA  2   phosphorylation in CTLs was dependent on their ac-
tivation status, we sorted freshly purifi  ed resting CD8      +   pe-
ripheral blood T cells that were used either immediately for 
biochemical studies or to establish a short-term eff  ector CTL 
line by allogenic stimulation, as previously described (  31  ). 
Interestingly, NKG2D and IL-15 failed to induce cPLA  2   
phosphorylation in resting CD8  +  TCR          +   peripheral blood 
lymphocytes, but not in the short-term derived eff  ector CTL 
line (Fig. S4, available at http://www.jem.org/cgi/content/
full/jem.20071887/DC1). These fi  ndings are in accordance 
with previously reported data (  6  ) showing that licensing of 
NKG2D by IL-15 to mediate cytolysis was restricted to CTLs 
in the eff  ector stage. 
  Finally, we investigated whether induction of cPLA  2   phos-
phorylation was associated with AA release (  Fig. 3  , right). This 
was investigated under conditions of stimulation resulting in 
and up-regulated cPLA  2   activity (Fig. S3 B), which were 
blocked in the presence of the pharmacological inhibitor CF3 
(Fig. S3). 
    Figure 2.         cPLA  2   activation is necessary for NKG2D cytolytic co-
stimulatory functions.   Inhibition of cPLA  2   blocks NKG2D augmentation 
of cytolytic T cell functions and AA reverses this blockage. Co-stimulation 
of cytolytic T cell functions by NKG2D was studied using three different 
PB-CTL clones (#411, #414, and #348) that were generated and cultured 
with low IL-2 (5 U/ml), in which NKG2D does not mediate direct cytolysis. 
Representative experiments of clone 411(top) and 414 (middle) are shown. 
PB-CTLs were pretreated with vehicle or CF3. Redirected cytolysis was 
performed against   51 Cr-labeled  FcgR +   P815 targets (E/T ratio of 50:1) in 
the presence of anti-CD3 mAbs at the indicated concentration in combi-
nation with either anti-NKG2D mAbs or isotype control IgG1 at fi  xed 
concentration (1   μ  g/ml). (bottom) A rescue experiment was performed by 
adding AA to CF3-pretreated cells 1 h after co-culture with target cells. A 
summary of three independent experiments for an anti-CD3 mAb concen-
tration of 12.5 ng/ml with means   ±   SD is shown. P values are from a 
Tukey-adjusted pairwise comparison.     
    Figure 3.     NKG2D and TCR engagement induce cPLA  2   phosphoryla-
tion and AA release in CTLs.   Celiac IE-CTL clone (A), PB-CTL clone (B), 
and TALL-104 CTLs (C) were studied. (left) Concentration-dependent cPLA  2  
phosphorylation upon NKG2D and TCR engagement. CTLs were serum 
starved for 16 h, and then stimulated for 15 min as indicated. Cell lysates 
were analyzed by Western blot using anti  –  phospho-cPLA  2   (p-PLA 2 ) – spe-
cifi  c antibody. The membrane was stripped and reblotted with anti-cPLA  2  
antibody to assess equal loading. (right) AA release upon NKG2D and TCR 
engagement. CTLs were incubated with   3  H-AA for 10 h, washed to remove 
free   3  H-AA, and stimulated with the indicated antibody or isotype control 
for 1 h. Supernatants and cell pellets were separately harvested. Total and 
released   3  H-AA were measured to determine the percentage of released 
  3  H-AA. Mean value of triplicates was used for each of the three experi-
ments. Data are means   ±   SD of three independent experiments. P values 
are from a Tukey-adjusted pairwise comparison.     JEM VOL. 206, March 16, 2009 
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  ERK and JNK regulate NKG2D-mediated cytolysis through 
cPLA  2   activation in CTLs 
  Previous studies had shown that NKG2D activated ERK and 
JNK through distinct pathways and that both MAP kinases 
regulated NKG2D-mediated cytolysis in CTLs in an additive 
manner (  6  ). However, how ERK and JNK played a role in 
cytolysis remained elusive. Interestingly, cPLA  2   activation by 
surface receptors was shown to be dependent on MAP kinase 
activation (for review see reference [  28  ]). This prompted us 
maximal levels of cPLA  2   phosphorylation. TCR stimulation 
induced AA release. However, importantly, NKG2D could 
induce AA release independently of TCR engagement. 
  Collectively, these results demonstrate that NKG2D can 
induce cPLA  2   activation and mediate AA release independently 
of TCR stimulation. This unexpected function of NKG2D 
suggests that in tissues expressing stress-induced ligands, CTLs 
could participate in the activation of granulocytes sensitive to 
the presence of AA. 
    Figure 4.         ERK and JNK control cPLA  2   activation and NKG2D-mediated cytolysis.   (A) JNK and ERK both regulate cPLA  2   phosphorylation and cy-
tolysis. Results shown were obtained with TALL-104 CTLs. Similar results were obtained with IE-CTLs. (top left) Phosphorylation time course. TALL-104 
CTLs were serum-starved for 16 h before stimulation with anti-NKG2D antibodies for the indicated time. Cell lysates were subjected to Western blot 
analysis by anti  –  phospho-ERK, -JNKK1, -JNK, and -cPLA  2  – specifi  c antibodies. (bottom left) ERK and JNK inhibitors block, in an additive manner, cPLA  2   phos-
phorylation. TALL-104 CTLs were pretreated with vehicle or suboptimal doses (10   μ  M) of specifi  c kinase inhibitors. PD 98059 (PD) and SP600125 (SP) are 
MEK1/2 and JNK inhibitors, respectively. cPLA  2   phosphorylation was determined by immunoblot with anti-phospho cPLA  2   after 15 min of stimulation with 
anti-NKG2D mAbs. Total cPLA  2   is shown as loading control. (right) AA signifi  cantly restored NKG2D-mediated cytolysis against C1R/MIC transfectants 
upon JNK, but not ERK, inhibition. TALL-104 CTLs were pretreated with vehicle and inhibitors as indicated in the top right graph. The rescue assay was 
done by addition of AA 1 h after co-culture of TALL-104 with   51  Cr-labeled C1R/MIC transfectants. Data are means   ±   SD of three independent cytolytic 
assays. (B) The Vav  → JNKK1/2 →  JNK pathway controls cPLA  2   phosphorylation. Phosphorylation experiments were performed on cells starved overnight 
and stimulated for the indicated time with anti-NKG2D antibodies. Western blots for phospho-JNK and -cPLA  2   were performed on total cell lysates using 
anti–phospho-JNK and -cPLA  2   antibodies. Vav phosphorylation was evaluated after immunoprecipitation with anti-Vav1 mAb and immunoblotting with 
anti-phosphotyrosine mAb. Equal loading for total lysates and for Vav 1 immunoprecipitation were assessed using anti-cPLA  2   and -Vav antibody, respec-
tively. (top left) Time course of anti-NKG2D–induced Vav phosphorylation. (top right) Dominant-negative Vav-1 (Vav 1-    C) blocked JNK and cPLA  2   activa-
tion. TALL-104 CTLs were transfected with control vector and Vav-    C and cultured for 48 h. Cells were then analyzed by Western blot as indicated. 
(bottom left) Dominant-negative JNKK2 blocks cPLA  2   phosphorylation. TALL-104 CTLs transfected with control vector and dominant-negative JNKK2(KM) 
were cultured for 48h and analyzed by Western blot. (bottom right) Constitutive JNK activation induced cPLA  2   phosphorylation. TALL-104 CTLs were 
transfected with JNKK2-JNK1 (which encodes a constitutively active form of JNK) or with JNKK2(KM)-JNK1 (which encodes a kinase-defi  cient mutant), in 
addition to GFP plasmids. After 40 h of transfection, cells were sorted by fl  ow cytometry into GFP  +   and  GFP       cells. Presence of p-cPLA  2   was evaluated by 
immunoblot in the absence of NKG2D stimulation. NKG2D-stimulated and nonstimulated TALL-104 CTLs, transfected with a control vector, served as pos-
itive and negative control for JNK and cPLA  2   phosphorylation. Equal loading was assessed by immunoblotting with total cPLA  2  . (C) ERK pathway regulates 
cPLA  2   phosphorylation. Dominant-negative and overexpression experiments were performed as in B. ERK and cPLA  2   phosphorylation were determined by 
Western blot. (left) Dominant-negative MEK-1 (MEK[2A]) signifi  cantly blocked cPLA  2   phosphorylation. (right) Constitutively active MEK-1 (MEK[2E]) in-
duced cPLA  2   phosphorylation in the absence of NKG2D stimulation.     712 CPLA  2  , IL-15, AND NKGD CYTOLYTIC FUNCTIONS   | Tang et al. 
to investigate whether there was a link between ERK, JNK, 
cPLA  2   activation, and NKG2D-mediated cytolysis. 
  We fi  rst determined the kinetic of ERK, JNK, and cPLA  2   
phosphorylation upon NKG2D stimulation. The peak of cPLA  2   
phosphorylation occurred at 10  –  15 min after ERK and con-
comitant with JNKK1 and JNK phosphorylation (  Fig. 4 A  , 
top left).   These results suggested that cPLA  2   phosphorylation 
was downstream of ERK and JNK. 
  To further evaluate the function of JNK and ERK in 
cPLA  2   activation and NKG2D-mediated cytolysis, we per-
formed studies with pharmacological inhibitors targeting 
specifi  c MAP kinases. As anticipated, cPLA  2   phosphorylation 
(  Fig. 4 A  , bottom left) and AA release (not depicted) were 
blocked in an additive manner upon ERK (PD98059) and 
JNK (SP600125) inhibition. In contrast, the p38 inhibitor SB 
203580 had no eff  ect (unpublished data), a result that is in 
agreement with its lack of function in NKG2D-mediated cy-
tolysis (  6  ). Finally, addition of AA reversed JNK inhibition, 
more signifi  cantly than ERK inhibition of NKG2D-medi-
ated cytolysis (  Fig. 4 A  , right). 
  We next dissected the signaling pathway leading to JNK 
activation and further assessed its critical role in cPLA  2   acti-
vation using a dominant-negative and overexpression ap-
proach. Vav1, which regulates JNK activation through a 
Rho/Rac1  →  MAPK kinase kinase 1 pathway (  32  ), was also 
reported to play an essential role in the NKG2D cytolytic 
pathway in NK cells (  33, 34  ). These observations suggested 
that Vav1 could control JNK activation. In agreement, our 
kinetic analysis indicated that Vav1 activation preceded 
JNKK1 and JNK phosphorylation (compare   Fig. 4, A and B  , 
top left). In addition, a dominant-negative of Vav1, Vav1-C 
(  33  ), blocked both JNK and cPLA  2   activation after NKG2D 
cross-linking in CTLs (  Fig. 4 B  , top right). To further assess 
the role of JNK in cPLA  2   phosphorylation, TALL-104 
CTLs were transfected with a dominant-negative JNKK2, 
which was shown to prevent JNK activation. As anticipated, 
blocking JNK activation resulted in inhibition of cPLA  2   
phosphorylation upon NKG2D engagement (  Fig. 4 B  , bot-
tom left). Conversely, simple overexpression of consti-
tutive active JNK (JNKK2-JNK1), but not inactive JNK 
(JNKK2[KM]-JNK1) (  35  ), induced similar levels of cPLA  2   
phosphorylation than NKG2D stimulation in CTLs (  Fig. 4 B  , 
bottom right). 
  Finally, because the upstream events leading to ERK acti-
vation were defi  ned by a previous study (  6  ) (see also   Fig. 7  ), 
we focused on assessing the role of ERK in cPLA  2   activation. 
As predicted by the pharmacological studies, the dominant-
negative of MEK-1 (MEK-2A) (  36, 37  ), which is located up-
stream of ERK, blocked ERK and cPLA  2   phosphorylation 
(  Fig. 4 C  , left), whereas overexpression of constitutive active 
MEK-1 (MEK-2E) (  36, 37  ), induced cPLA  2   phosphorylation 
(  Fig. 4 C  , right). 
  Altogether, these observations suggest that Vav is up-
stream of JNK, and that JNK and ERK control NKG2D-
mediated cPLA  2   activation in CTLs in an independent and 
additive manner. 
  Figure 5.       IL-15 promotes NKG2D-mediated cytolytic degranula-
tion, cPLA  2   activation, and AA release in primary IE-CTLs.  (A)  IL-15 
up-regulates cPLA  2   expression, and induces ERK, JNK, and cPLA  2   activa-
tion in fresh IE-CTLs. (left) IL-15 induces ERK, JNK, and cPLA  2   phosphory-
lation in a time-dependent manner. Fresh IE-CTLs were starved overnight 
and stimulated with 20 ng/ml IL-15 for indicated time periods. Cell lysates 
were immunoblotted with anti-p-ERK, -p-cPLA, and -p-cPLA  2   antibodies. 
Total ERK and total cPLA  2   are shown to assess equal loading. (right) Fresh 
IE-CTLs were cultured with IL-15 or IL-7 for 48 h. cPLA  2   expression  was 
determined by Western blot. Equal loading was assessed using an anti-
CD3     mAb. (B) IL-15 synergizes with NKG2D to induce cPLA  2   phosphory-
lation in a dose- (left) and time-dependent (right) manner. Fresh IE-CTLs 
(left) or TALL-104 CTLs (right) were stimulated with IL-15 alone, anti-
NKG2D mAb alone, or IL-15 in combination with anti-NKG2D mAb for 
15 min at the indicated concentration (left), or for the indicated time at 
saturating concentrations (4   μ  g/ml anti-NKG2D mAb and 20 ng/ml IL-15) 
(right). For each panel one out of 2 representative experiments is shown. 
(C and D) IL-15 stimulation plays a critical role in NKG2D-mediated cPLA  2  
activity (C) and cytolytic granule release (D) in primary IE-CTLs. Freshly 
purifi  ed IE-CTLs were cultured with or without IL-15 (20 ng/ml) for 24  –  48 h 
and pretreated for 30 min with vehicle control or CF3 before stimulation 
with anti-NKG2D mAb or IgG1 isotype control. Rescue experiments were 
performed by adding 50   μ  M of AA after 1 h of stimulation. Data are 
means   ±   SD of six experimental points from two independent experi-
ments. P values are from a Tukey-adjusted pairwise comparison. (E) IL-15 
enhances NKG2D-mediated AA release. Fresh IE-CTLs were cultured with 
or without IL-15 (10 ng/ml) for 24 h and analyzed for AA release upon 1 h 
stimulation. (left) IE-CTLs were not stimulated (NS) or stimulated with 
plate-bound anti-NKG2D mAb (4   μ  g/ml). (right) IE-CTLs were stimulated 
with control EL-4 cells or MICA-transfected EL4 cells (MICA/EL-4) 
at a IE-CTLs to target cell ratio of 1:0.5. Data are means   ±   SD of three 
independent experiments. P values are from a Tukey-adjusted 
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inspection and background staining, automatic image analysis 
was performed using the ACIS software (see Materials and 
methods) as previously described (  39, 40  ). Specifi  c cPLA  2   
staining appears in red when staining is above background 
threshold values after overlay (  Fig. 6 A  ). Importantly, the 
  IL-15 arms NKG2D to mediate cytolysis and AA release 
in primary IE-CTLs by up-regulating cPLA  2   expression 
and activation 
  We had previously demonstrated that IL-15 or high levels of 
IL-2 (which can substitute for IL-15) licensed NKG2D to me-
diate cytolysis independently of TCR activation in eff  ector 
CTLs (  6, 13  ). Furthermore, we showed that IE-CTLs exposed 
in vivo to IL-15 in active celiac disease killed MIC  +   target cells 
(  6  ). Here, we investigated whether the licensing of NKG2D to 
mediated direct cytolysis in freshly purifi  ed IE-CTLs involved 
cPLA  2   activation by IL-15. We fi  rst determined whether IL-15 
could activate cPLA  2  . Interestingly, IL-15 induced not only 
ERK and JNK phosphorylation, as previously shown (  6, 38  ), 
but also cPLA  2   phosphorylation ( Fig. 5 A , left).  The time course 
was similar to that of NKG2D (compare   Fig. 5 A  , left, and   Fig. 
4 A  , left). In addition, cPLA  2   expression was increased in pri-
mary IE-CTLs stimulated for 48 h with IL-15, but not with 
IL-7 (  Fig. 5 A  , right). Furthermore, IL-15 synergized with 
NKG2D to induce cPLA  2   phosphorylation in a dose- (  Fig. 5 B  , 
left) and time-dependent manner (  Fig. 5 B  , right). cPLA  2   activ-
ity was signifi  cantly up-regulated only in freshly isolated IE-
CTLs that were prestimulated with IL-15 for 48 h. Importantly, 
induction of cPLA  2   activity paralleled the ability of NKG2D to 
mediate degranulation (compare   Fig. 5, C and D  ). Conversely, 
cPLA  2   inhibition blocked cPLA  2   activity (  Fig. 5 C  ) and de-
granulation (  Fig. 5 D  ), which was restored in the presence of 
AA (  Fig. 5 D  ). 
  We next investigated whether NKG2D could induce AA 
release in primary eff  ector IE-CTLs. As shown in   Fig. 5 E  , IL-
15 and NKG2D independently induced AA release. The release 
was maximal when IE-CTLs were stimulated simultaneously 
by IL-15 and NKG2D. Importantly, AA release was also ob-
served upon engagement of NKG2D by plate-coated mono-
clonal anti-NKG2D mAb (  Fig. 5 E  , left) and MIC-expressing 
EL4 fi  broblasts (  Fig. 5 E  , right). 
  Altogether, these observations suggest that priming of the 
NKG2D cytolytic pathway by IL-15 in primary eff  ector CTLs 
entails up-regulation of cPLA  2   expression and activation. Fur-
thermore, IL-15 and NKG2D can induce AA release. 
  Expression of phosphorylated cPLA  2   in IE-CTLs 
of celiac patients 
  NKG2D and IL-15 were shown to play a critical role in ce-
liac disease by licensing IE-CTLs to kill enterocytes (  6  ). Fur-
thermore, previous studies in active celiac patients reported 
that ERK (  6  ) and JNK (  38  ) phosphorylation were induced in 
IE-CTLs of active celiac patients. Together, these observa-
tions suggested that cPLA  2   might be activated in IE-CTLs of 
celiac patients. 
  In situ analysis of immunohistochemical staining with 
anti-CD3 antibody in combination with anti–phospho-cPLA  2   
antibody or control antibody revealed that the frequency of 
IE-CTL  –  expressing phospho-cPLA  2   was highly increased in 
celiac patients (  n   = 6; 79   ±   8%) compared with controls (  n   = 
4; 13   ±   4.6%; P = 0.001) (  Fig. 6 B  ).   In addition, to control 
for evaluation bias inherent to subjective morphological 
    Figure 6.     Phospho-cPLA  2   expression in IE-CTLs of active celiac 
patients.   (A) Representative examples of double staining immunohisto-
chemistry of CD3 (brown)/phospho-cPLA  2   (blue) in duodenal biopsies 
from patients with active celiac disease and controls (magnifi  cation 
     200). Intraepithelial lymphocytes were randomly selected from the pool 
of CD3  +  cells and automatically numbered as shown. Expression of phos-
pho-cPLA  2   was measured within each outlined CD3  +   IE-CTLs. In the left 
images, before overlay, phospho-cPLA  2  —positive appears in blue. After 
overlay, in the right images, specifi  c phospho-cPLA  2   staining as deter-
mined by threshold values is highlighted in red. (insets) IE-CTL #23 and 
#24 before and after applying the overlay tool. Note that double-positive 
IE-CTL #23 falls within the threshold values for phospho-cPLA  2 —positive 
staining and thus is covered with solid red in overlaid image. In contrast, 
IE-CTL #24 falls below the threshold values for phospho-cPLA  2 —positive 
staining and thus remains covered with white in overlaid image. Finally, 
increased phospho-cPLA  2  —positive epithelial cells (colored in red after 
overlay) are present in active celiac patients compared with controls. Bars: 
(a) 40   μ  m; (b) 10   μ  m. (B) A summary with mean percentage of phospho-
cPLA  2  +   IE-CTLs   ±   SD is presented after manual and automated count. For 
manual count, four control and six celiac patients were analyzed. For 
automated count,   >  100 IE-CTLs in two control and two celiac slides were 
analyzed. P value was determined with the exact Wilcoxon rank sum test. 
Note that manual and automated count give similar percentage of 
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cule associated with NKR-P1A remains undefi  ned. Thus, 
the role of cPLA  2   could not be ascribed to particular cyto-
lytic signaling pathways and to individual NK receptors in 
human. Our study unambiguously identifi  es the NKG2D–
DAP10 in human CTLs as an immunoreceptor complex that 
requires cPLA  2   activation and AA release as integral compo-
nents of its cytolytic machinery. In addition, our preliminary 
data indicate that this fi  nding is not limited to CTLs, because 
the NKG2D cytolytic pathway in NK cells also involves 
cPLA  2   activation (unpublished data). Interestingly, our data 
suggest that cPLA  2   is not signifi  cantly involved in TCR-me-
diated cytolysis. Future studies will determine whether, more 
generally, ITAM-signaling receptors mobilizing high levels 
of calcium mediate granule exocytosis independently of 
cPLA  2  . In agreement, NK cell receptors associated with 
ITAM-bearing adaptor molecules induce high levels of cal-
cium fl  ux (  47  ) and cPLA  2  -independent cytolysis (  56  ). Im-
portantly, however, even though cPLA  2   is not directly 
involved in TCR-mediated cytolysis, it plays a critical role 
in the co-stimulation of cytolytic T cell responses. Notably, 
automatic count confi  rmed the manual count by showing a 
similar signifi  cant increase in the percentage of cPLA  2  -positive 
IE-CTLs (  Fig. 6 B  ). This result is even more striking in regard 
to the augmentation in the number of IE-CTLs in celiac disease, 
reaching classically up to 10 times the value of that observed in 
normal controls (  41  ). The total number of IE-CTL  –  expressing 
phospho-cPLA  2   in celiac patients can therefore be estimated to 
be 40  –  60-fold higher than in controls. This fi  nding is particu-
larly relevant in the context of our observations that cPLA  2   plays 
a critical role in NKG2D cytolytic functions of celiac and IL-
15  –  stimulated IE-CTLs (  Figs. 1 and 5  ). 
  Furthermore, phospho-cPLA  2  , similar to phospho-ERK 
and JNK (  6, 38  ), was also highly up-regulated in enterocytes of 
celiac patients (  Fig. 6 A  ), especially in the nuclear compartment 
(not depicted) where accumulation correlates with activation 
(for review see reference [  28  ]). 
  Altogether, these results illustrate that cPLA  2   is activated in 
IE-CTLs of active celiac patients and support, in association 
with other present (  Figs. 1 and 5  ) and past (  6  ) observations, an 
in vivo role for cPLA  2   in celiac disease pathogenesis. 
    DISCUSSION   
  Our study establishes an unexpected connection between 
Il-15– and CTL-mediated immunopathology in celiac disease 
and infl  ammatory lipid biology. Our observations also suggest 
that NKG2D eff   ector functions, particularly cytolysis, are 
critically regulated by cPLA  2   in CTLs. Furthermore, we iden-
tify an unexpected role for Vav, JNK, and ERK in NKG2D-
mediated cytolysis by showing that they mediate cPLA  2   
activation. Finally, our study suggests that NKG2D and IL-15 
could contribute to tissue infl  ammation and granulocyte acti-
vation by promoting the release of AA in CTLs (  Fig. 7  ).   
  The molecular basis for exocytosis is a fi  eld of high inves-
tigation. It involves traffi     cking of granules to the plasma 
membrane and membrane fusion events. There is increasing 
evidence that exocytosis can be triggered, either under con-
ditions of high-level calcium mobilization suffi   cient to ac-
tivate snare-mediated membrane fusion (for review see 
references [  42  ]), or under conditions of low levels of calcium 
mobilization (  43  ) involving AA and its eicosanoids metabo-
lites, which are known as fusogens (  44  ). This latter mecha-
nism is thought to play a role in neutrophil and neuroendocrine 
cell degranulation (  45, 46  ). It may be particularly relevant for 
surface receptors that, similar to NKG2D, signal through an 
adaptor molecule lacking an ITAM motif (  10  ), and induce 
relatively low levels of calcium (  34  ,   47  ) (Fig. S5, available at 
http://www.jem.org/cgi/content/full/jem.20071887/DC1). 
Pharmacological studies performed in the 1980s (  48  –  52  ) 
suggested that infl  ammatory lipid mediators may play a role 
in NK cell  –  mediated lysis in human and rodents without 
defi  ning the receptors involved (  48  –  52  ). More recently, 
cPLA  2   was proposed to contribute to NKR-P1A  –  induced 
cytolysis in rat NK cells (  53  ). However, recent fi  ndings in 
human indicate that engagement of NKR-P1A by its ligand 
LLT1 (  54, 55  ) inhibited rather than induced NK cell  –  medi-
ated lysis (  54  ). Furthermore, the nature of the adaptor mole-
    Figure 7.     Model of the NKG2D signaling pathway in CTLs.   The 
NKG2D cytolytic signaling pathway involves PLC-    2, Vav1, and PI3-K 
activation (  60  ). How these upstream signaling events are interconnected 
in CTLs remains to be determined. NKG2D-mediated cytolysis requires 
activation of cPLA  2   and AA release, suggesting that the level of calcium 
mobilization achieved upon NKG2D cross-linking is insuffi  cient to allow 
membrane fusion events and exocytosis. Cytosolic PLA  2   activation itself is 
mediated through two independent pathways, Vav-1  → JNKK1/2 →
 JNK1/2 → cPLA 2   and  PI3-K → MEK1/2 → ERK → cPLA 2  . It is likely that these 
pathways also promote granule polarization (  62, 63, 67  ). In addition, 
cPLA  2   activation is also required for NKG2D cytolytic co-stimulatory func-
tions. Interestingly, IL-15, which licenses NKG2D killing in CTLs (  6  ), en-
hances NKG2D-mediated JNK, ERK and cPLA  2   phosphorylation, and AA 
release. Once released, AA can potentially be reincorporated into phos-
pholipids, mediate the biosynthesis of eicosanoids and induce 
granulocyte activation.     JEM VOL. 206, March 16, 2009 
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expression, and activation of the PI3-K  →  ERK signaling path-
way (  6  ). We now show that IL-15 is also involved in the ac-
tivation of JNK. More importantly, we demonstrate that 
IL-15  –  mediated licensing of the NKG2D cytolytic pathway 
requires cPLA  2   activation, and that cPLA  2   is highly activated 
in IE-CTLs of active celiac patients. Interestingly, cPLA  2   is 
concomitantly activated in the intestinal epithelial cells. This 
activation of cPLA  2   may be secondary to the activation of 
enterocytes by IL-15 (  74  ) and/or AA released by IE-CTLs. 
  Finally, our study reveals that NKG2D and IL-15 signaling 
in eff  ector CTLs causes CTLs to release AA and potentially 
eicosanoids, such as leukotrienes and prostaglandins. Eicosanoid 
synthesis by CTLs is supported by our fi  ndings that NKG2D 
induces AA production and activates 5-LO and COX (unpub-
lished data). Interestingly, AA and eicosanoids favor granu-
locyte recruitment and activation (  75  –  79  ). These fi  ndings 
establish an unrecognized link between CTLs, NKG2D, IL-
15, and infl  ammation, which may have as of yet unrecognized 
patho  lo  gical implications. In particular, it may be relevant in 
immune-mediated diseases, such as rheumatoid arthritis and 
celiac disease, where NKG2D and IL-15 play a pathogenic role 
(for review see reference [  15  ]) and where granulocytes are acti-
vated (  80  –  84  ). 
  Collectively, our fi  ndings invite us to reexamine the role 
of IL-15 and NKG2D in infl  ammation and autoimmunity, 
and develop therapeutic strategies aimed at blocking cPLA  2   
in diseases associated with dysregulated IL-15 expression and 
NKG2D activation. Future studies will determine whether 
5-LO and COX should also be targeted. Our preliminary 
observations suggest that 5-LO, but not COX, is involved in 
NKG2D-mediated immunopathology. In addition, in view 
of observations suggesting that prostaglandins inhibit NK cell 
cytolytic responses (  85, 86  ), blocking COX activation may 
even be deleterious. 
    MATERIALS AND METHODS   
  Human subjects.     For immunohistochemical studies, six adult patients with 
active celiac disease and four control aged-matched individuals undergoing 
biopsies for functional intestinal disorders of nonceliac origin were studied. 
Diagnosis of celiac disease was based on detection of antitransglutaminase 
antibodies, the presence of HLA DQ2 or DQ8, villous atrophy, and clinical 
and histological response to a gluten-free diet. In addition, IE-CTLs were 
isolated from surgical specimens of individuals undergoing gastric bypass for 
morbid obesity, as previously described (  6  ). All subjects gave written in-
formed consent and research was approved by the University of Chicago In-
stitutional Review board. 
  CTL isolation and cell culture.     IE-CTLs were purifi  ed from jejunal bi-
opsies and surgical specimens, as previously described (  31  ). Intraepithelial and 
peripheral blood NKG2D  +  TCR  +  CD8  +   CTL lines and clones were obtained 
and cultured as previously described (  31  ). PB-CTL clone #348 and #414 
(cultured with 5 U/ml of IL-2) in which NKG2D exerts co-stimulatory cy-
tolytic functions but cannot induce direct cytolysis were obtained and cul-
tured, as previously described ( 1, 8 ). Resting peripheral blood CD8  +  TCR          +   
T lymphocytes were purifi  ed and an eff  ector CTL line was generated accord-
ing to a previously described protocol (  6, 31  ). In brief, peripheral blood lym-
phocytes were isolated from whole blood of healthy volunteers after Ficoll 
density gradient centrifugation (GE Healthcare). Cells were stained with anti-
CD8     APC-conjugated mAb (BD) and purifi  ed by AutoMACS (Miltenyi 
NKG2D was unsuccessful to induce cPLA  2   phosphorylation 
in resting CD8  +  TCR          +   peripheral blood lymphocytes. 
This fi  nding may explain why NKG2D fails to exert co-
stimulatory function in resting noneff  ector CD8 T cells (  57  ). 
Together, these observations are in agreement with the gen-
eral concept, reported by Bryceson et al. (  58, 59  ) that recep-
tors using diff  erent adapters and signaling pathways contribute 
distinctively and synergistically to cytolysis. 
  Studies had identifi  ed PLC-    2, PI3-K, and Grb2/Vav1 as 
key upstream signaling molecules of the NKG2D cytolytic 
pathway (  Fig. 7  ) (  33, 60, 61  ). Our previous analysis of the hu-
man NKG2D–DAP10 cytolytic signaling pathway suggested 
that ERK and JNK, activated through independent pathways, 
played critical roles in NKG2D- but not TCR-mediated cy-
tolysis (  Fig. 7  ) (  6  ). The role of PI3K in cytolysis is complex 
and remains incompletely understood; among its potential 
roles, PI3K is thought to be involved in ERK activation (  6, 
62, 63  ). A critical role for Vav in natural killer signaling and 
cytotoxicity has been reported in mouse and human by several 
groups (  33, 64  –  68  ). Vav is thought to play a role similar to 
that of ERK (  62, 63  ) in cytolysis by promoting granule polar-
ization (  67  ). This study reveals that Vav1 is upstream of JNK 
in the NKG2D cytolytic pathway (  Fig. 7  ). More importantly, 
it sheds a new light on the role of the PI3K  –  ERK and Vav  –
  JNK pathways in NKG2D-mediated cytolysis by showing 
that ERK and JNK critically regulate cPLA  2   activation, which 
in turn critically regulates NKG2D-mediated degranulation 
and cytolysis (  Fig. 7  ). Whether AA, which is released upon 
cPLA  2   activation, plays a role in granule exocytosis as fusogen 
(  22, 44, 45  ) or indirectly through its role in the biosynthesis of 
eicosanoids remains to be determined. AA serves as a substrate 
to 5-LO and cyclooxygenase (COX), which drive the leukot-
riene and prostaglandin synthesis pathways, respectively (  28  ). 
Interestingly, although NKG2D engagement induces 5-LO 
and COX activation, only 5-LO is involved in NKG2D-me-
diated cytolysis (unpublished data). These observations are in 
agreement with reports suggesting that leukotrienes, but not 
prostaglandins, play a role in lymphokine-activated killer ac-
tivity (  51, 52  ) and NK-mediated cytolysis (  69, 70  ). 
  Convergent observations suggest that IL-15 and NKG2D 
may coordinately regulate CTL eff  ector functions and medi-
ate organ-specifi  c immunopathology (for review see reference 
[  15  ]). For instance, the role of NKG2D as a direct mediator of 
cytolysis was shown in celiac disease (  6  ). Celiac disease is an 
infl  ammatory intestinal disorder with an autoimmune compo-
nent triggered by dietary gluten in genetically susceptible 
individuals (  71, 72  ). Although the role of gluten-specifi  c, 
DQ2- or DQ8-restricted CD4 T cells in the lamina propria 
was accepted early on (  73  ), the role of IE-CTLs was ques-
tioned because no gluten-specifi  c IE-CTLs could be identi-
fi  ed (for review see reference [  71  ]). Our fi  nding that IL-15 
primed NKG2D in CTLs to kill MIC-expressing enterocytes 
in celiac disease (  6, 13  ) provided an explanation as to how IE-
CTLs could cause intestinal damage and malabsorption, de-
spite their inability to recognize gluten. Licensing by IL-15 
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the indicated antibodies, followed by HRP-conjugated goat anti  –  mouse 
(HRP-GAM) or donkey anti  –  rabbit (HRP-DAR) antibodies (Jackson 
Immunoresearch Laboratories) using the enhanced chemiluminescence (ECL) 
kit from GE Healthcare. Tyrosine-phosphorylated Vav1 was revealed by an-
tiphosphotyrosine (4G10) antibody after immunoprecipitation of the cell ly-
sates with rabbit polyclonal anti-Vav1 antibody. 
  Cytotoxicity assay.     Chromium release assays were performed as previ-
ously described using P815 cells (a Fc      +   mouse mastocytoma; American 
Type Culture Collection), C1R-MICA1, EL4-MICA1, control C1R 
transfectants, and control EL4 cells at the indicated E:T ratio in triplicate 
wells (  6  ). For Fc-dependent redirected cytotoxicity, eff  ectors and targets 
were incubated in the presence of soluble anti-NKG2D or anti-CD3 
mAbs at the indicated concentration. Chromium release was measured us-
ing a scintillation counter (Packard). Maximum release was determined by 
the addition of detergent (10% SDS) and spontaneous release ranged 
from 5  –  10% of the maximum. The percentage of specifi  c cytotoxicity was 
calculated using the formula 100  ×   (cpm experimental     cpm spontaneous)/
(cpm maximum      cpm spontaneous). When indicated, eff  ector cells were 
treated for 30 min before and during the cytotoxic assay with diff  erent 
inhibitors, lipid mediators, or equivalent concentrations of the DMSO or 
ethanol vehicles. 
  AA release assay.     10  6   cells/ml IE-CTLs, PB-CTLs, and TALL-104 CTLs 
were labeled with 0.2   μ  Ci   3  H AA (specifi  c activity 62.5 Ci/mmol; Perkin-
Elmer) in RPMI 1640 or IMDM with 0.2% fetal bovine serum at 37  °  C 5% 
CO  2   for 1 or 8 h. After labeling, cells were washed at least three times to re-
move free   3  H AA and, when indicated, pretreated with inhibitors or vehicles 
for 30 min in medium with 0.2% bovine serum albumin (BSA). Cells were 
then incubated with anti-NKG2D, anti-CD3 mAbs, or mouse IgG1 control 
at 37  °  C for 4 min followed by F(ab')  2   goat anti  –  mouse IgG for 1 h in me-
dium with 0.2% BSA. Supernatants and cell pellets were separately collected 
by centrifugation.   3  H AA was measured with a scintillation counter. Per-
centage of   3  H AA release was calculated as supernatant   3  H/(supernatant   3  H + 
pellet   3  H)   ×   100. 
  Flow cytometric analysis.     For surface staining, cells were incubated with 
fl  uorochrome-conjugated antibodies according to standard protocols. Fluo-
rescence was analyzed on a six-color FACSCanto (Becton Dickinson) with 
quadrants set to score as negative   >  99% of control Ig-stained cells. 
  Measurement of granule release by BLT esterase assay.     Granule re-
lease was evaluated as previously described (  6  ). In brief, CTLs were sus-
pended in RPMI medium containing 2% FCS, incubated in 96-well with 
4   μ  g/100   μ  l of anti-NKG2D mAb or isotype control for 4 min, and then 
stimulated for 4 h with goat anti  –  mouse IgG F(ab  '  )  2   at 37  °  C. Maximum 
granule release was determined using 1% Triton X-100. The supernatants 
were evaluated for esterase secretion using a standard N-benzyloxycarbonyl 
lysine thiobenzyl ester (BLT; Calbiochem). The percentage of BLT esterase 
activity was calculated using the following equation: (experimental BLT es-
terase release      spontaneous BLT esterase release)/(maximum BLT esterase 
release      spontaneous BLT esterase release)   ×   100. 
  cPLA  2   enzyme activity assay.     cPLA  2   activity was assessed in lysates of 
primary IE-CTL, PB, and IE-CTL lines according to the manufacturer  ’  s 
procedure (Cayman Chemical), as reported (  87  ), using arachidonoyl thio-
PC as a synthetic substrate. In brief, 4   ×   10  6   cells were stimulated with 
anti-NKG2D or isotype control, and the pellets were lysed by three cycles 
of freeze thawing in lysis buff  er (50 mM Hepes, pH 7.4, containing 1 mM 
EDTA, 1   μ  g/ml leupeptin, 5   μ  g/ml aprotinin, 1 mM PMSF, 2 mM Na  3  VO  4  , 
2.5 mM NaF, and 1 mM DTT). 10   μ  l sample supernatant and 5   μ  l assay buf-
fer were well mixed and the reaction was initiated by adding 200   μ  l substrate 
solution to the wells. After 1 h incubation at room temperature, 10   μ  l of 
DTNB/EGTA was added to each well to stop the reaction. Absorbance 
was measured at 414 nm. cPLA  2   activity was expressed as the percentage of 
Biotec) using anti-APC magnetic beads (Miltenyi Biotec). Purity (  >  95%) of 
isolation was confi  rmed by fl  ow cytometry. Purifi  ed CD8  +  TCR          +   T cells 
were divided into two parts. One part was directly used for cPLA  2   signal 
transduction experiments. The other part was used to generate a short-term 
eff  ector CTL line by allogenic stimulation, as previously described (  31  ), to 
investigate whether the eff  ector status impacted on the ability of NKG2D to 
induce cPLA  2   phosphorylation. 
  MICA-transfected (C1R-MIC) or control vector  –  transfected (C1R-
Neo) C1R cells and CD8  +  TCR          +   cytotoxic leukemia TALL-104 cell line 
(American Type Culture Collection) were cultured, as previously described 
(  6  ). EL4 (American Type Culture Collection TIB-39) are a murine T lym-
phoma cell line. MICA-transfected EL4 (EL4-MICA) and control EL4 cells 
were grown in RPMI 1640 supplemented with 10% FCS, glutamine, antibi-
otics, and G 418. 
  Reagents, antibodies, and recombinant cytokines.     cPLA  2   inhibitor 
AACOCF3, MEK1/2 inhibitor PD98059, and JNK inhibitor SP600125 were 
obtained from Calbiochem. AA and LA were obtained from Sigma-Aldrich. 
Anti-CD3 (clone UCHT1, IgG1) and anti-NKG2D mAbs (clone 1D11, IgG1) 
and isotype-matched control IgG1 were purchased from BD; PE-conjugated 
anti-NKG2D 1D11 was purchased from eBioscience; and anti-Vav1, -cPLA  2  , 
-ERK, -JNK-phospho-cPLA  2  , -phospho-JNKK1, -phospho-PLC    2, -phos-
pho-ERK, and -phospho-JNK antibodies were purchased from Cell Signaling 
Technology. Antiphosphotyrosine mAb 4G10 was obtained from Millipore. 
Antiactin mAb was purchased from Sigma-Aldrich. Anti  –  5-LO mAb was ob-
tained from Fitzgerald Industries Int. F(ab  '  )  2   goat anti  –  mouse antibodies were 
obtained from Jackson ImmunoResearch Laboratories. Human IL-15 and IL-2 
were purchased from BD. 
  Plasmids, siRNA, and transfection.     Dominant-negative mutant Vav1 
plasmid (pcDNA3.fl  ag.h.Vav1-C) that contains only the C-terminal portion 
of Vav1 was a gift from P. Leibson and D. Billadeau (Mayo Clinic College of 
Medicine, Rochester, MN,) (  33  ). Dominant-negative MEK1(S218a, S222a, 
MEK[2A]), and constitutively activated MEK1(MEK[2E]) expression plasmid 
were gifts from M.R. Rosner (University of Chicago, Chicago, IL) (  36, 37  ). 
Expression vectors encoding JNKK2-JNK1 (which encodes a constitutively 
active form of JNK), JNKK2(K149M)-JNK1 (a kinase-defi  cient mutant), and 
JNKK2(KM) have been previously described (  35  ). cPLA  2  , 5-LO, and control 
synthesized siRNA oligonucleotides were purchased from Santa Cruz Bio-
technology, Inc. TALL-104 CTL cells were electroporated with the Amaxa 
Nucleofector (Amaxa, Inc.), using Amaxa Cell Line nucleofection solution V 
and program T-20. Cells were cultured for 24  –  72 h before being used for ex-
periments. For overexpression experiments involving HA-tagged JNKK2-
JNK1, HA-tagged JNKK2(KM)-JNK1, or MEK(2E), TALL-104 CTLs were 
cotransfected with the indicated plasmids and GFP plasmid at a 5:1 ratio. 40 h 
after transfection, cells were sorted by fl  ow cytometry into GFP  +   and GFP        
cells with FACSAria (BD) before being analyzed for p-cPLA  2  , p-JNK, and p-
ERK expressions by Western blot. For siRNA experiments, 4   ×   10  6   cells were 
transfected with 120 pmol siRNA and 30 pmol GFP plasmid. On average, 
40% of cells were transfected based on GFP expression. Effi   ciency and speci-
fi  city of protein knock-down was assessed by Western blot with the appropri-
ate antibodies. 
  Cell signaling.     To look at cPLA  2  , JNK, and ERK phosphorylation, cells 
were serum-starved for 30 h. To test the eff  ects of kinase inhibitors, cells 
were preincubated for 30 min at 37  °  C with the indicated inhibitors before 
stimulation. To cross-link immunoreceptors, cells were incubated for 4 min 
at 4  °  C with the indicated monoclonal antibody before adding F(ab'    )  2   GAM 
for the indicated duration at 37  °  C. Cells were lysed for 20 min in ice-cold 
lysis buff  er containing fresh protease and phosphatase inhibitors (50 mM 
Tris-Hcl [pH 7.5]; 150 mM NaCl; 1% Triton-X100; 1 mM EDTA; 1 mM 
Na  3  VO  4  ; 1 mM NaF; and protease inhibitor cocktail tablets). Cellular debris 
was removed by centrifugation at 15,000 rpm for 20 min at 4  °  C. Total ly-
sates were subjected to SDS-PAGE electrophoresis and transferred to PVDF 
membranes (Bio-Rad Laboratories). Proteins were then detected by using JEM VOL. 206, March 16, 2009 
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used at 1:50 dilution. 
  To control for evaluation bias inherent to subjective morphological in-
spection and background staining, automatic image analysis with the pixel 
and cell/object-based image analysis was performed using ACIS software 
from Clarient, as previously described (  39, 40  ). For each slide, 5  –  6 areas 
were scanned at 200  ×   magnifi  cation to yield high-resolution digital images. 
The ACIS software applies the color-specifi  c  thresholds  confi  gured  by 
an experienced user-pathologist (MT) to diff  erentiate specifi  c blue phos-
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  For analysis of immunohistochemical data, celiac cases were compared 
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  Online supplemental material.     Fig. S1 shows dose-dependent inhibition 
by AACOCF3 (CF3) and rescue by AA of NKG2D-mediated cytolysis. Fig. S2 
shows the eff  ect of cPLA2 inhibition by AACOCF3 (CF3) on granzyme 
and perforin expression in IE- and PB-CTLs. Fig. S3 shows that NKG2D 
stimulation induces perinuclear cPLA2 translocation and cPLA2 activity in 
IE- and PB-CTLs in a time-dependent manner. Fig. S4 shows that NKG2D 
and IL-15 induce cPLA2 phosphorylation in eff  ector, but not resting, pe-
ripheral blood CTL. Fig. S5 shows that NKG2D induces notably lower 
levels of calcium release than the TCR in CTLs. A supplemental materials 
and methods is also provided. Online supplemental material is available at 
http://www.jem.org/cgi/content/full/jem.20071887/DC1. 
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